Literature DB >> 18083712

EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.

Kotha Subbaramaiah1, Clifford Hudis2, Sung-Hee Chang3, Timothy Hla3, Andrew J Dannenberg4.   

Abstract

Cytochrome P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from androgens. Because aromatase-dependent estrogen biosynthesis has been linked to hormone-dependent breast carcinogenesis, it is important to elucidate the mechanisms that regulate CYP19 gene expression. The main objective of this study was to identify the receptors (EP) for prostaglandin E(2) (PGE(2)) that mediate the induction of CYP19 transcription in human adipocytes and breast cancer cells. Treatment with PGE(2) induced aromatase, an effect that was mimicked by either EP(2) or EP(4) agonists. Antagonists of EP(2) or EP(4) or small interference RNA-mediated down-regulation of these receptors suppressed PGE(2)-mediated induction of aromatase. PGE(2) via EP(2) and EP(4) stimulated the cAMP-->protein kinase A pathway resulting in enhanced interaction between P-CREB, p300, and the aromatase promoter I.3/II. Overexpressing a mutant form of p300 that lacks histone acetyltransferase activity suppressed PGE(2)-mediated induction of aromatase promoter activity. PGE(2) via EP(2) and EP(4) also caused a reduction in both the amounts of BRCA1 and the interaction between BRCA1 and the aromatase promoter I.3/II. Activation of the aromatase promoter by PGE(2) was suppressed by overexpressing wild-type BRCA1. Silencing of EP(2) or EP(4) also blocked PGE(2)-mediated induction of the progesterone receptor, a prototypic estrogen-response gene. In a mouse model, overexpressing COX-2 in the mammary gland, a known inducer of PGE(2) synthesis, led to increased aromatase mRNA and activity and reduced amounts of BRCA1; these effects were reversed by knocking out EP(2). Taken together, these results suggest that PGE(2) via EP(2) and EP(4) activates the cAMP-->PKA-->CREB pathway leading to enhanced CYP19 transcription and increased aromatase activity. Reciprocal changes in the interaction between BRCA1, p300, and the aromatase promoter I.3/II contributed to the inductive effects of PGE(2).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083712     DOI: 10.1074/jbc.M705409200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.

Authors:  Noriyuki Omura; Margaret Griffith; Audrey Vincent; Ang Li; Seung-Mo Hong; Kimberly Walter; Michael Borges; Michael Goggins
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.

Authors:  Kotha Subbaramaiah; Neil M Iyengar; Monica Morrow; Olivier Elemento; Xi Kathy Zhou; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

4.  Estrogen Protects against Obesity-Induced Mammary Gland Inflammation in Mice.

Authors:  Priya Bhardwaj; Baoheng Du; Xi Kathy Zhou; Erika Sue; Dilip Giri; Michael D Harbus; Domenick J Falcone; Clifford A Hudis; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-02

5.  Prostaglandin E2 (EP) receptors mediate PGE2-specific events in ovulation and luteinization within primate ovarian follicles.

Authors:  Soon Ok Kim; Siabhon M Harris; Diane M Duffy
Journal:  Endocrinology       Date:  2014-02-07       Impact factor: 4.736

6.  Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.

Authors:  Neil M Iyengar; Kristy A Brown; Xi Kathy Zhou; Ayca Gucalp; Kotha Subbaramaiah; Dilip D Giri; Heba Zahid; Priya Bhardwaj; Nils K Wendel; Domenick J Falcone; Hanhan Wang; Samantha Williams; Michael Pollak; Monica Morrow; Clifford A Hudis; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2017-03-07

7.  Cyclooxygenase-2 enzyme induces the expression of the α-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer.

Authors:  Daisy Sproviero; Sylvain Julien; Brian Burford; Joyce Taylor-Papadimitriou; Joy M Burchell
Journal:  J Biol Chem       Date:  2012-12-28       Impact factor: 5.157

Review 8.  Genetics of androgen metabolism in women with infertility and hypoandrogenism.

Authors:  Aya Shohat-Tal; Aritro Sen; David H Barad; Vitaly Kushnir; Norbert Gleicher
Journal:  Nat Rev Endocrinol       Date:  2015-05-05       Impact factor: 43.330

9.  Hsp90 and PKM2 Drive the Expression of Aromatase in Li-Fraumeni Syndrome Breast Adipose Stromal Cells.

Authors:  Kotha Subbaramaiah; Kristy A Brown; Heba Zahid; Gabriel Balmus; Robert S Weiss; Brittney-Shea Herbert; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2016-06-01       Impact factor: 5.157

10.  PPARγ agonists target aromatase via both PGE2 and BRCA1.

Authors:  Ofer Margalit; Dingzhi Wang; Raymond N Dubois
Journal:  Cancer Prev Res (Phila)       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.